Pharma To Date

Eli Lilly has broadened its collaboration with Oblique Therapeutics, enhancing their strategic alliance initially established in November 2023. The expansion focuses on leveraging Oblique’s AbiProt platform to discover high-value therapeutic antibodies targeting both soluble and membrane-bound proteins.

Oblique’s AbiProt platform utilizes advanced microfluidics and protease-based molecular probes to identify specific antibody-binding sites on native-state proteins. This innovative approach has previously demonstrated success, notably in targeting the TRPV1 pain channel, which has been challenging for small molecule antagonists due to adverse side effects.

The newly expanded partnership includes exploring additional targets beyond the TRPV1 channel. Lilly’s commitment to advancing pain management and oncology through this collaboration underscores its strategic emphasis on innovative therapies. The AbiProt platform's capability to provide sequence and structural data for precise epitope identification positions it as a valuable tool in drug discovery.

Oblique Therapeutics is poised to benefit significantly from this extended alliance. CEO Christer Nordstedt expressed enthusiasm about the partnership's potential to address severe unmet medical needs, particularly through novel antibody development. The collaboration with Lilly Catalyze360-ExploR&D aims to generate new science, contributing to advancements in the antibody discovery domain and potentially leading to valuable milestones and royalties.

By combining Lilly’s substantial R&D expertise with Oblique’s cutting-edge technology, the initiative promises to drive progress in areas with critical medical needs and enhance treatment options for complex diseases.

As Lilly and Oblique forge ahead, the outcomes of this expanded partnership will be closely watched for their potential to revolutionize therapeutic approaches and address significant challenges in drug development.